Research Progress of Ropeginterferon α-2b in Treatment of Myeloproliferative Neoplasm --Review.
10.19746/j.cnki.issn.1009-2137.2025.01.047
- Author:
Ling-Rong TU
1
;
Jian HUANG
2
Author Information
1. Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, Zhejiang Province, China.
2. Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
- Publication Type:English Abstract
- Keywords:
myeloproliferative neoplasms;
ropeginterferon α-2b;
interferon-alpha;
therapy
- MeSH:
Humans;
Interferon-alpha/therapeutic use*;
Myeloproliferative Disorders/drug therapy*;
Polyethylene Glycols/therapeutic use*;
Recombinant Proteins/therapeutic use*;
Interferon alpha-2;
Polycythemia Vera/drug therapy*
- From:
Journal of Experimental Hematology
2025;33(1):306-310
- CountryChina
- Language:Chinese
-
Abstract:
Ropeginterferon α-2b (Ropeg), a novel, long-acting pegylated prolene alpha interferon, is the first interferon specifically approved for the treatment of patients with polycythemia vera (PV), and has been found in clinical trials and experience to induce hematologic remission, control disease-related symptoms, and reduce JAK2V617F allelic burden in patients with myeloproliferative neoplasms (MPNs). It has a lower incidence and severity of adverse drug reactions than pegylated interferon alpha and hydroxyurea and a longer dosing interval. Some patients with lowrisk PV and myelofibrosis can benefit from it. This article reviews the latest progress of Ropeg in MPN.
